Evidence map›Paper›PMID 30614531›Full record

ArticleInternational journal of cancer2019

Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.

Dominik Paul Modest, Fernando Rivera, Jean-Baptiste Bachet, Filippo de Braud, Filippo Pietrantonio, Reija Koukakis, Gaston Demonty, Jean-Yves Douillard

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00364013 phase3completednot on this map

A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic Colorectal Cancer

TypeinterventionalSponsorAmgenRan2006 to 2013Enrolled1,183ConditionsMetastatic Colorectal CancerArmsPanitumumab, FOLFOX regimen
NCT00819780 phase2completednot on this map

A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer

TypeinterventionalSponsorAmgenRan2009 to 2016Enrolled285ConditionsColon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal CancerArmsPanitumumab, Bevacizumab, mFOLFOX6
3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy forJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Trial
  2. Trial
  3. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Comprehensive review of targeted therapy for colorectal cancer.Signal transduction and targeted therapy · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dominik Paul ModestDepartment of Medicine III & Comprehensive Cancer Center, Hospital of the University (LMU) Grosshadern, Ludwig-Maximilians-University, Munich, Germany.ORCID 0000-0002-6853-0599
Fernando RiveraDepartment of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Jean-Baptiste BachetDepartment of Gastroenterology, La Pitié-Salpetrière Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
Filippo de BraudMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Filippo PietrantonioMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-8530-8420
Reija KoukakisDepartment of Biostatistics, Amgen Ltd, Uxbridge, United Kingdom.
Gaston DemontyMedical Development, Amgen (Europe) GmbH, Rotkreuz, Switzerland.
Jean-Yves DouillardDepartment of Medical Oncology, Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Panitumumab is approved for RAS wild-type metastatic colorectal cancer and was evaluated in Phase III (PRIME, NCT00364013) and Phase II (PEAK, NCT00819780) first-line randomised studies. This retrospective analysis of these trials investigated efficacy and toxicity of panitumumab-based maintenance after oxaliplatin discontinuation in RAS wild-type patients. First-line regimens were FOLFOX4 ± panitumumab in PRIME and mFOLFOX6 plus panitumumab or mFOLFOX6 plus bevacizumab in PEAK. Outcomes included median progression-free survival (PFS) and overall survival (OS), from randomisation and oxaliplatin discontinuation, and toxicity. Overall, median duration of panitumumab plus 5-fluorouracil/leucovorin (5-FU/LV) maintenance was 21 (interquartile range: 11-41) weeks; that of 5-FU/LV ± bevacizumab maintenance was 16 (6-31) weeks. Median OS from randomisation was 40.2 (95% confidence interval: 30.3-50.4) and 39.1 (34.2-63.0) months for panitumumab plus 5-FU/LV maintenance and 24.1 (17.7-33.0) and 28.9 (21.0-32.0) months for 5-FU/LV ± bevacizumab maintenance in PRIME and PEAK, respectively. Median PFS from randomisation was 16.6 (11.3-23.6) and 15.4 (11.6-18.4) months for panitumumab plus 5-FU/LV maintenance and 12.6 (9.4-16.2) and 13.1 (9.5-16.6) months for 5-FU/LV ± bevacizumab maintenance in PRIME and PEAK, respectively. From oxaliplatin discontinuation, median OS was 33.9 (24.7-42.8) and 33.5 (24.5-54.9) months for panitumumab plus 5-FU/LV maintenance and 16.4 (12.4-24.1) and 23.3 (15.7-26.3) months for 5-FU/LV ± bevacizumab maintenance in PRIME and PEAK, respectively; PFS was 11.7 (7.8-19.2) and 9.7 (5.8-14.8) months and 7.1 (5.6-10.2) and 7.0 (3.9-10.6) months, respectively. The most frequently reported adverse events were rash, fatigue and diarrhoea. Maintenance of panitumumab plus 5-FU/LV after oxaliplatin discontinuation was well tolerated and may be an acceptable treatment paradigm for patients demonstrating a good response to first-line treatment. Prospective studies are warranted.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBevacizumabClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicColorectal NeoplasmsFemaleFluorouracilHumansLeucovorinMaintenance ChemotherapyMaleMiddle AgedNeoplasm MetastasisBevacizumabFluorouracilLeucovorinOrganoplatinum CompoundsOxaliplatinPanitumumabepidermal growth factor receptormaintenancemetastatic colorectal cancerpanitumumabsurvivaltoxicity

Identifiers

PMID30614531
PMCPMC6590196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.